v

...

1
57
.
:
1.
10 mg : LDL 110 mg/dl, HDL 34
mg/dl, TG 114 mg/dl
2. ( 4)
3. 20 / 40
:
1. 2,
2.

1
:
1.
&
2.S1, S2 ,
3. ,

4.
5.: , ,
,BMI:27
6. :
a)
b)
c)

: 152/85 mmHg
: 155/87 mmHg
: 160/90 mmHg (: 1.03, )

1
:

?
1.
2.
3.

<120

<80

120-129

80-84

130-139

85-89

140-159

90-99

160-179

100-109

180

110

140

<90

Mancia G, Fagard R, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial
hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2013; 34:
2159-2219

24 -

, ,
, /
,
stress
24 : ,
. , , -
24
:
, ,
,

24 ..

(
1 ,..
/
)
(
.. ,..

/ )
ESH/ESC 2013

 ..

1
2 :
HBPM:
: 147.8 / 84.2 mmHg
: 151,3 / 87,1 mmHg

140

90

135

85

120

70

130

80

135

85

24
( )
( )
24

:

Mancia G, Fagard R, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial
hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2013; 34:
2159-2219

1
(),
()

(mmHg)
/

1-2

, 3,

,




4, /

: , : , : , :
-
Mancia G, Fagard R, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial
hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2013; 34:
2159-2219


..>=60mmHg
HK : ...
TRIPLEX:LMVindex >3.5mV,>1.1mV

(>0.9mm)-
>0.9
...(eGFR:30-60)

1
:

?
1. 24
2.
3. /
4.
5.Triplex &
6.K+, Na+, , ,
7.
8.1, 6

1

:


, HDL, LDL,
&

eGFR (MDRDC/G)

(dipstick ,
24, )
.
Mancia G, Fagard R, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial
hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2013; 34:
2159-2219

1
,
,
:

&
24

holter

Mancia G, Fagard R, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial
hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2013; 34:
2159-2219

1

(,
, ) -
,
.

Mancia G, Fagard R, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial
hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2013; 34:
2159-2219

1
H :
S/R 82 bpm

(+) Sokolow

1
2 :
Triplex :


MV & AV

1
,
& 2 :
& HBPM:
: 145.1 / 81.2 mmHg
: 155,3 / 84,1 mmHg

:
0,9 eGFR 88 mL/min
24: 38 gr
AST 24, ALT 35, K+ 4.1, Na+ 138

1
57
, ,

(),
()

&

&
&








&
1-2

&
&








&
&
3

&

&
&
&
, 3,

, 4,
&
&
&

: , : , : , :

1
:

?
1.AMEA ARB
2.CCB
3.Thiazide diuretic
4.B-Blocker
5.1+2
6.1+2+3

(,, )
- (, ,)


A
ESH/ESC2013

1
57
,

1
57
,

1
57
,

,



.

,

.
,
,
( , CCB, ACEI, ARB)

.
BP 2 ,
( , CCB, ACEI, ARB),
ACEI & ARB

,
,

, ,
,

.
2 ,
( , CCB, ACEI, ARB),
- ARB.
.

2
, 2

2 , 2
.
2 , > 160 mm Hg / > 100
mm Hg, > 20 mm Hg / > 10 mm Hg
.

1
57
,

1
0 , ,.
:5mgr
: 10mgr( LDL

39%)
O ,

2
68 7
.
:I 300/HCTZ25+A 10mgr
WBC:6600,Ht:42,2,PLT:189000
:93mg/dl,:47mg/dl,cr:1,04mg/dl,K/Na:3,9/138mEq/L
T-CHOL:205mg/dl,HDL:77,LDL:113,.:75mg/dl
:
1.2
2. Hashimoto TSH: 2,2
:
1. ,.. ...
2. Parkinson & Alzheimer

2
:
1.
2.S1, S2 & (85bpm),
3. ,

4.
5.
6.: , ,
,:29
7. ( 3 )
a)
b)

: 162/85 mmHg
: 165/87 mmHg

2
:

?
1.
2.


.. { ..>140/90 mmHg}

3
, .
..
5-30%
<10%

,..,,
,..,..


-
..

(
)
(NSAID,S,,))
A

,

?
1 /
..
2 24 ..
3
4
5 1+4
6 2+3+4
7

,,

, .
.

:
,

< 40

(

)

,

,
eGFR

>
1.5
2 ,
Triplex

eGFR (

, spiral
,

per os,

, CT
,

U/S NOK

. /

/ .

,
,
,

,
.

(
)

Cushing

,
,
,

,
,
, buffalo
hump

24

CT MRI
,

2
ABPM:H:AVG:144/88mmHg
:77.8%>135mmHg/=23%>85mmHg
ABPM:N:146/72mmHg >120=100%/=67%>70mmHg
U/S : o /. 0,6
cm.A 12 cm
1,5 cm
Triplex : . . 30%
20% .
Triplex - :
60-70%.
60-70%
C/T :X
riplex :EF>60%,
24:25mgr/24,GFR:65ML/MIN/1.73m
:0,95

 68
,

A
/



<2gr

( GFR>50mL/min)
30-45mins
24>100mEq

(
)
12,5-25mgr
A

2-3
/24 X,N,N,



160mgr/10mgr/HCTZ25 mgr
.
25mgr
20 mgr +ASA 100 mgr

BPM
,/,//
triplex
. stress-echo

, 68 , ,

: 163cm, : 88 kg, : 31kg/m2, W: 100cm

. .:
..: 165/95 mmHg

:
Glu: 115mg/dl , U:35 , Cr:0,90, eGFR:96,51 , TChol:257mg/dl
HDL: 34mg/dl
LDL: 149 mg/dl , TG: 220 mg/dl , UA: 8.4 mg%,
: (-),ALT:43,AST:40,-GT:39

: , (48 )
2

3
:
1.
2.S1, S2 , 75 bpm
3. ,
4.
5. s
6. HBPM: 155-145mmHg & 90-95mmHg

3
2 :

Triplex :

Triplex :

U/S :
,

3

5%-10% ..

160mgr/HCTZ12,5mgr
E 10 mgr

3
:

?
1.
2.


?
.
.
. -
ACEIs ARBs
. (-Blockers)

2013 ESH, ESC Guidelines:

Treatment strategies in hypertensive patients with
metabolic syndrome or prediabetes

G. Mancia et al EHJ June 2013

,


(/)

( , ).


-
300 mgr+
5mgr
E 40 mgr
E 2

:
?
1. Losartan ABPM &
HBPM >160mmHg
140-150

:
?
1. Losartan ABPM &
HBPM >160mmHg
140-150

:
?
2. Losartan CCB DU 140150mmHg

:
?
3. Losartan 120-140mmHg

:
?
3. Losartan 120-140mmHg

:
?
3. Losartan 120-140mmHg

:
?
3. Losartan 120-140mmHg

:
?

1
,
& 2 :
& HBPM:
: 145.1 / 81.2 mmHg
: 155,3 / 84,1 mmHg

:
0,9 eGFR 88 mL/min
24: 38 gr
AST 24, ALT 35, K+ 4.1, Na+ 138

24 ..

(
1 ,..
/
)
(
.. ,..

/ )
ESH/ESC 2013

2
:

?
1.,
2., (WCH)
3., (masked HT)
4.,

, 68, ..

:
?
1. Losartan ABPM &
HBPM >160mmHg
2. Losartan CCB DU 140150mmHg
3. Losartan 120-140mmHg

80

20 Losartan 50 mg 1X1

(
2 , ).
:
1. 24
2. 98
.

3
H :
S/R 72 bpm

(-) Sokolow

3
:

?
1.
2.


-

300 mgr
E 40 mgr
E 2